Results 201 to 210 of about 392,226 (299)

Neoadjuvant Therapy for Localized Pancreatic Cancer. [PDF]

Cancers (Basel)
McKean J, Underwood P, Yasinzai AQK, George T, Sahin I, Fabregas J, Qumseya B, Novikov A, Chua T, Paniccia A, Hitchcock KE, Hughes S, Nassour I.   +12 more
europepmc   +1 more source

Preoperative Gemcitabine/Nab‐Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer: A Comparative Analysis With Preoperative Chemoradiation Therapy Using Gemcitabine Alone

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Although NCCN guidelines recommend preoperative therapy for borderline resectable pancreatic cancer (BR‐PC), it is still unclear which regimen is better. The study objective was to elucidate the prognostic significance of neoadjuvant chemoradiotherapy (NACRT) with gemcitabine/nab‐paclitaxel (GnP‐RT) compared to gemcitabine alone ...
Hirofumi Akita, Hidenori Takahashi, Yousuke Mukai, Masahiko Kubo, Shinichiro Hasegawa, Masayoshi Yasui, Takeshi Omori, Hiroshi Miyata, Hiroshi Wada, Kunihito Gotoh   +9 more
wiley   +1 more source

Exploration of Optimal Synergistic Treatment Strategies of Postoperative Radiotherapy and Immunotherapy in Early-Stage Breast Cancer. [PDF]

Cancers (Basel)
Shang Q, Wang H, Zhuang Y, Plichta JK, Thomas SM, Ouyang M, Luo S, Wang X.   +7 more
europepmc   +1 more source

Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization

Annals of Gastroenterological Surgery, EarlyView.
This review summarizes key advances from 2024 to 2025 that are reshaping esophageal cancer surgery toward a strategy‐oriented, personalized paradigm through the integration of immunotherapy, population aging, and intelligent technologies. Adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only perioperative approach with durable benefit,
Shuichiro Oya, Koichi Yagi, Yoshifumi Baba   +2 more
wiley   +1 more source

Contemporary Adjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasms.

JAMA Netw Open
Lucocq J, Haugk B, White S, Marchegiani G, Holmberg M, Zerbi A, Pagnanelli M, Lu Z, Inoue Y, Choi M, Kang CM, Visser B, Corpelijn L, Andersson B, Bereza-Carlson P, Björnsson B, Wennerblom J, Labori KJ, Goh BKP, Hartman V, Ahmad S, Patel S, Berrevoet F, Mortensen K, Roberts K, Ausania F, Lynch C, Gupta A, Bertrand C, Kleeff J, Addeo P, Bellotti R, Ven Fong Z, Friess H, Koea J, Gomez D, Gordon-Weeks A, Doria C, Tzimas G, Franklin O, Månsson C, Cabús SS, Bhogal RH, Pathak S, Honselmann KC, Balakrishnan A, Harrison E, Mann K, Gill AJ, Mittal A, Samra J, Athwal T, Loveday B, Teh C, Bhardwaj N, Menon K, Thapa P, Matsumoto I, Jamieson N, Rebours V, Descourvieres C, Davidson B, Soreide K, Pandanaboyana S, Adeno-IPMN2 Collaborative.   +64 more
europepmc   +1 more source

Neoadjuvant and/or adjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced resectable penile squamous cell carcinoma. [PDF]

Front Immunol
Xu S, Chen F, Diao L, Wang W, Wang X, Wu Q, Sun P, Hao Y, Wang Y, Ji R, Jiang Y, Du J, Ang B, Yang Q, Zhao Z.   +14 more
europepmc   +1 more source

Effect of Broad‐Spectrum Antibiotic Prophylaxis on Post‐Pancreatoduodenectomy Infectious Complications: Nationwide Inpatient Database Study in Japan

Annals of Gastroenterological Surgery, EarlyView.
Using a nationwide Japanese inpatient database, we evaluated whether broad‐spectrum antibiotic prophylaxis improves postoperative outcomes after pancreatoduodenectomy compared with narrow‐spectrum antibiotics. In propensity score–weighted analyses of 45 099 patients, broad‐spectrum prophylaxis was associated with significantly lower rates of intra ...
Hiroki Kitagawa, Shotaro Aso, Yuki Hirano, Kenichiro Uemura, Keita Kouzu, Satoru Matsuda, Hiroki Matsui, Kiyohide Fushimi, Junichi Sasaki, Yuko Kitagawa, Hideo Yasunaga   +10 more
wiley   +1 more source

External Beam Radiation Therapy for Intrahepatic Cholangiocarcinoma. [PDF]

J Gastrointest Cancer
Hotca AE, Feng M.
europepmc   +1 more source

Management Strategies for Disappearing Colorectal Liver Metastases After Systemic Chemotherapy: Long‐Term Outcomes and Preoperative Prediction of ‘True Complete Response’

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Determining whether to resect disappearing liver metastases (DLMs) after chemotherapy for colorectal liver metastases (CRLMs) remains challenging. Methods Patients who underwent hepatectomy after systemic chemotherapy for initially unresectable CRLMs were reviewed. True complete response (CR) was defined as either resected DLMs with
Taihei Soma, Ryo Ashida, Takeshi Kawakami, Katsuhisa Ohgi, Mihoko Yamada, Shimpei Otsuka, Yoshiyasu Kato, Kentaro Yamazaki, Katsuhiko Uesaka, Teiichi Sugiura   +9 more
wiley   +1 more source

Adjuvant chemotherapy for completely resected stage IB-IIA non-small cell lung cancer according to the AJCC 8th edition staging system: a real-world retrospective cohort study based on the SEER database. [PDF]

Transl Lung Cancer Res
Sun Z, Zhao C, Feng K, Chang G, Zhang J, Ju Y, Yang F, Yan X, Li X.   +8 more
europepmc   +1 more source